{
    "2020-05-17": [
        [
            {
                "time": "2023-10-01",
                "original_text": "高瓴资本在美首季持有60只个股，市值超过74亿美元",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "美股",
                        "持仓",
                        "市值"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "400亿定增资金‘围猎’医药生物股",
                "features": {
                    "keywords": [
                        "定增",
                        "医药生物",
                        "资金流入"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "首席观点：美国限制我国进口半导体问题愈发明显，军工电子板块有望受益",
                "features": {
                    "keywords": [
                        "美国",
                        "半导体",
                        "军工电子",
                        "政策限制"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "军工",
                        "电子"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "高瓴资本连下三城背后 400亿定增资金‘围猎’医药生物股",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "定增",
                        "医药生物",
                        "投资策略"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}